Highbridge Capital Management LLC increased its position in Bristol-Myers Squibb Co (NYSE:BMY) by 1,197.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,734 shares of the biopharmaceutical company’s stock after acquiring an additional 33,534 shares during the quarter. Highbridge Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $1,908,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Cypress Capital Management LLC WY increased its holdings in Bristol-Myers Squibb by 154.7% in the 3rd quarter. Cypress Capital Management LLC WY now owns 1,910 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 1,160 shares in the last quarter. CSat Investment Advisory L.P. purchased a new stake in Bristol-Myers Squibb in the 2nd quarter worth approximately $113,000. Landaas & Co. WI ADV purchased a new stake in Bristol-Myers Squibb in the 2nd quarter worth approximately $131,000. CLS Investments LLC increased its holdings in Bristol-Myers Squibb by 194.3% in the 3rd quarter. CLS Investments LLC now owns 2,575 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 1,700 shares in the last quarter. Finally, Selective Wealth Management bought a new position in Bristol-Myers Squibb in the 3rd quarter worth approximately $184,000. 72.74% of the stock is owned by institutional investors.
NYSE BMY opened at $53.08 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.53 and a debt-to-equity ratio of 0.41. The company has a market cap of $86.91 billion, a PE ratio of 14.31, a PEG ratio of 1.48 and a beta of 1.11. Bristol-Myers Squibb Co has a one year low of $46.94 and a one year high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.18. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. On average, sell-side analysts expect that Bristol-Myers Squibb Co will post 3.87 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, February 1st. Stockholders of record on Friday, January 4th will be given a dividend of $0.41 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date is Thursday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is currently 53.16%.
Several research firms have weighed in on BMY. ValuEngine upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday. Barclays upped their price target on Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Friday, October 12th. Credit Suisse Group restated a “hold” rating and issued a $61.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, September 12th. William Blair restated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Monday, October 22nd. Finally, Citigroup downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $62.00 to $57.00 in a research note on Monday, October 22nd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have issued a buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $61.95.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Featured Article: Insider Trading
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.